COMPASS Pathways (CMPS) stock may be fully priced following Phase 3 data release. Phase 3 data release has led to full valuation of COMPASS Pathways stock with limited additional upside ahead.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2025 | ‡‡‡ |
|
| 2024 | ‡‡‡ |
|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 220.64 | 165.47 | 149.99 | 433.72 |
| Receivables | 1.12 | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 261.30 | 201.29 | 191.49 | 475.67 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 5.89 | 12.28 | 15.22 | 12.24 |
| ST’ Debt | — | 5.51 | 17.52 | — |
| Other | — | — | 203.73 | 337.46 |
| 19.60 | 34.02 | 247.80 | 367.29 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡ | ‡‡‡ |
| Year |
|---|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (47.94) | (40.31) | — | — |
—
|
| ’25 | (45.66) | (38.69) | (35.11) | (37.79) |
(157.24)
|
| ’24 | (20.83) | (34.42) | (22.18) | (41.76) |
(119.19)
|
| ’23 | (27.72) | (24.81) | (17.06) | (27.78) |
(97.38)
|
| ’22 | (23.12) | (18.00) | (19.02) | (45.30) |
(105.45)
|
| ’21 | (13.78) | (17.70) | (13.89) | (22.37) |
(67.74)
|
| ’20 | (4.46) | (6.25) | (13.91) | (16.75) |
(41.38)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (47.94) | (40.31) | — | — |
—
|
| ’25 | (45.66) | (38.69) | (35.11) | (37.79) |
(157.24)
|
| ’24 | (20.83) | (34.42) | (22.18) | (41.76) |
(119.19)
|
| ’23 | (27.75) | (24.83) | (17.08) | (27.78) |
(97.44)
|
| ’22 | (23.20) | (18.42) | (19.02) | (45.41) |
(106.05)
|
| ’21 | (13.85) | (17.79) | (13.98) | (22.46) |
(68.08)
|
| ’20 | (4.50) | (6.30) | (13.92) | (16.78) |
(41.51)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.30) | (1.88) | — | — |
—
|
| ’25 | (0.24) | (0.41) | (1.44) | (1.00) |
(3.08)
|
| ’24 | (0.55) | (0.56) | (0.56) | (0.63) |
(2.30)
|
| ’23 | (0.57) | (0.62) | (0.67) | (0.53) |
(2.32)
|
| ’22 | (0.50) | (0.50) | (0.43) | (0.73) |
(2.16)
|
| ’21 | (0.35) | (0.44) | (0.38) | (0.61) |
(1.79)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡ | 6.54 | 5.01 | 3.59 | 2.25 | — | — | — |
Low Price
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 23.22 | 11.15 | 12.75 | 7.15 | — | — | — |
High Price
|
| — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 181 | 186 | 166 | 156 | — | — | — |
Employees
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Gross Margin
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (91.10) | (117.68) | (153.53) | (290.33) | — | — | — |
EBT
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (91.50) | (118.46) | (155.12) | (287.86) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.33 | 0.24 | 0.23 | 0.22 | — | — | — |
Depreciation
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.16) | (2.32) | (2.30) | (3.08) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.48) | (1.91) | (1.77) | (1.68) | ‡‡‡‡‡ | — | — |
Cash Flow/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.01) | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.50) | (1.91) | (1.77) | (1.68) | — | — | — |
Free CF/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.27 | 4.42 | 2.29 | (0.57) | ‡‡‡‡ | — | — |
Book Value/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 42.44 | 51.03 | 67.48 | 93.51 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (105.45) | (97.38) | (119.19) | (157.24) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.60) | (0.06) | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (106.05) | (97.44) | (119.19) | (157.24) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 176.06 | 241.69 | 167.28 | (56.30) | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | — | ‡‡‡‡‡ | 0.42 | 28.76 | 30.17 | 31.63 | — | — | — |
Total Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (142.96) | (191.88) | (135.30) | (118.35) | — | — | — |
Net Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 181.28 | 225.74 | 154.70 | (52.85) | — | — | — |
Sh' Equity
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (36.73%) | (50.06%) | (63.36%) | (135.78%) | — | — | — |
ROA
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (180.08%) | (252.71%) | (574.41%) | 0.00% | — | — | — |
ROIC
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (39.30%) | (58.21%) | (81.55%) | (565.28%) | — | — | — |
ROE
|
Compass Pathways (CMPS), a clinical-stage biotech pioneering psilocybin therapy COMP360 for treatment-resistant depression, holds Breakthrough Therapy Designation and Phase 3 trial momentum amid a post-COVID mental health crisis. Yet, its balance sheet raises red flags: cumulative losses have ballooned to $155 million in 2024 from $13 million in 2018, driven by relentless cash burn—operating cash flow down 22% to -$119 million—funded largely through 800% share dilution that eroded book value per share by 80% to $2.29. With no revenue until 2025 projections, deeply negative ROA (-0.63%) and ROE (-0.82%), and persistent free cash flow deficits, the company exemplifies biotech fragility in a high-rate environment squeezing unprofitable firms.
The stock has cratered 79% from 2020 peaks to $12.75, trading well below analyst targets implying 158% mean upside (up to 589% high), but this reflects binary trial risks rather than steady value creation. Insider silence over 12 months offers no conviction signal, while projections show losses widening to -$217 million in 2025 before modest EPS improvement. Macro tailwinds like psychedelic decriminalization and a $100 billion depression market exist, but execution hurdles—trial failures, regulatory delays, further dilution—loom large.
For risk-averse investors, CMPS is a high-volatility catalyst play demanding vigilant monitoring of 2025-2026 Phase 3 data; while asymmetric upside beckons on success, downside protection is thin absent partnerships or capital efficiency gains.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.